Harmony Biosciences saw a welcome improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 85 to 91.
This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. The rating shows how a stock's price performance over the last 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the best stocks often have an RS Rating north of 80 as they begin their largest runs.
Looking For The Best Stocks To Buy And Watch? Start Here
While Harmony Biosciences is not near an ideal entry right now, see if it is able to form and break out of a proper base.
The company showed 6% EPS growth in the latest quarterly report. Sales rose 16%.
Harmony Biosciences earns the No. 2 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics is the No. 1-ranked stock within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
